ANI Pharmaceuticals (ANIP) reported Q4 adjusted earnings Friday of $1.63 per diluted share, up from $1 a year earlier.
Analysts polled by FactSet expected $1.44.
Revenue for the quarter ended Dec. 31 was $190.6 million compared with $131.7 million a year earlier.
Analysts surveyed by FactSet expected $175.4 million.
The company said it expects 2025 adjusted earnings of $6.12 to $6.49 per diluted share. Analysts surveyed by FactSet expect $5.56.
The company raised its revenue for the year to a range of $756 million to $776 million from a range of $739 million to $759 million. Analysts polled by FactSet expect $724.9 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。